[Clinic-pathologic characteristics of @entity792 combined with XXXX ].

@entity1 @entity706 @entity5 @entity3726 @entity31 @entity784 @entity30 @entity3191 @entity2282 @entity4042 @entity14546 @entity1892 @entity1893 @entity10632 @entity792 @entity309
This study was aimed to investigate the clinical characteristics and treatment of @entity1 with @entity792 combined with @entity1893 ( @entity1893 ). The clinical characteristics and pathologic patterns of 6 @entity1 with @entity1893 who concurrently suffered from @entity792 were analysed retrospectively from aspects of clinical course, pathologic features, and therapy. Treatment outcomes for @entity792 and @entity1893 were observed. The results showed that 6 @entity1 included 4 females and 2 males, range in age from 28 to 65 years with a median age of 56 years. The @entity792 are @entity10632 ( @entity10632 , 2 cases), @entity309 ( @entity309 , 2 cases), @entity31 ( @entity31 , 1 case) and @entity30 ( @entity30 , 1 case). The @entity1893 located not only in the lymph node (n = 3) but also in extranodal sites (n = 3). Histologically, 3 cases were @entity1892 ( @entity1892 ), 2 cases were extranodal nasal NK/ @entity784 (ENKL) and 1 case was @entity3191 , not otherwise specified. Based on @entity2282 , @entity4042 and @entity14546 expression patterns, all 3 @entity1892 were classified as non-GC subtype. EBER positive @entity5 cells were detected in 2 case of ENKL. 5 @entity1 achieved a complete remission (83%) and 1 @entity1 was primary drug-resistant after @entity3726 chemotherapy or involved radiotherapy. Median survival from the time of @entity706 diagnosis was 3 years. 1 @entity1 showed clinical improvement of the @entity10632 symptoms, 2 @entity1 ( @entity30 and @entity31 ) showed stable state of disease and 2 @entity1 with @entity309 and 1 @entity1 with @entity10632 needed continuing treatment for their @entity792 after chemotherapy for @entity1893 . It is concluded that the development of @entity1893 is one of the most serious complications in @entity1 with @entity792 . There is an increased frequency of non-GC subtype @entity1892 . @entity3726 combined with or without radiotherapy proves to be effective for @entity792 @entity1 with aggressive @entity1893 but ineffective for concurrent @entity792 .
